// App-Quantinova.ai

8507 : A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.

Researchers

Presenter

  • Dean Anthony Fennell

Principal Investigators

  • Angela Claire Casbard

  • Catharine Porter

  • Robin Rudd

  • Jason Francis Lester

  • Marianne Nicolson

  • Bruno Morgan

  • Jeremy Peter Steele

  • Liz Darlison

  • Georgina Mary Gardner

  • Lisette Sheena Nixon

  • Terri Kitson

  • Ann White

  • Gareth Owen Griffiths

  • Charlotte Poile

  • Aarti Gaba

  • Sara Busacca

  • Catherine Jane Richards

Medical Centers

  • University of Leicester and University Hospitals of Leicester, Leicester, United Kingdom

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Cardiff University, Cardiff, United Kingdom

  • Department of Histopathology, St. Bartholomews Hospital, London, United Kingdom

  • Swansea Bay University Health Board, Swansea, Wales, United Kingdom

  • Aberdeen Royal Infirmary, Aberdeen, United Kingdom

  • University of Leeds, Leeds, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Malignant pleural mesothelioma

  • Solid malignancies

Biomarkers

  • Vimentin

Drug/Treatment

  • Vinorelbine

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT02139904

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved